Survival in Lymph Node Negative Adenocarcinoma of the Esophagus after R0 Resection With and Without Neoadjuvant Therapy: Evidence for Downstaging of N Status

Journal of the American College of Surgeons

Volumn 208, Issue 4, 2009, Pages 553-556

  Leers, Jessica M ^a   Ayazi, Shahin ^a   Hagen, Jeffrey A ^a   Terterov, Sergei ^a   Klipfel, Nancy ^b   Oezcelik, Arzu ^a   Abate, Emmanuele ^a   Lipham, John C ^a   DeMeester, Steven R ^a   Banki, Farzaneh ^a   DeMeester, Tom R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 62349141015     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2009.01.017     Document Type: Article

References (16)

1. Malthaner R.A., Collin S., and Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 3 (2006) CD001556
2. Fiorica F., Di Bona D., Schepis F., et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53 (2004) 925-930
3. Refaely Y., and Krasna M.J. Multimodality therapy for esophageal cancer. Surg Clin North Am 82 (2002) 729-746
4. Reynolds J.V., Muldoon C., Hollywood D., et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245 (2007) 707-716
5. Schneider P.M., Baldus S.E., Metzger R., et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 242 (2005) 684-692
6. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
7. Law S., Fok M., Chow S., et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 114 (1997) 210-217
8. Jiao X., Krasna M.J., Sonett J., et al. Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer. Eur J Cardiothorac Surg 19 (2001) 880-886
9. Urschel J.D., Vasan H., and Blewett C.J. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 183 (2002) 274-279
10. Rice T.W., Blackstone E.H., Adelstein D.J., et al. Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg 125 (2003) 1091-1102
11. Portale G., Hagen J.A., Peters J.H., et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 202 (2006) 588-596
12. Peyre C.P., Hagen J.A., DeMeester S.R., et al. Predicting systemic recurrence of esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 248 (2008) 979-985
13. Rice T.W., Blackstone E.H., Adelstein D.J., et al. N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Cardiovasc Surg 121 (2001) 454-464
14. Chirieac L.R., Swisher S.G., Ajani J.A., et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103 (2005) 1347-1355
15. Swisher S.G., Hofstetter W., Wu T.T., et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241 (2005) 810-817, discussion 817-820
16. Rizk N.P., Venkatraman E., Bains M.S., et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 25 (2007) 507-512